Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 417 Thousand EUR | 11.8% |
| 2022 | 373 Thousand EUR | -4.85% |
| 2021 | 392 Thousand EUR | 22.5% |
| 2020 | 320 Thousand EUR | -17.31% |
| 2019 | 387 Thousand EUR | -5.61% |
| 2018 | 410 Thousand EUR | -13.34% |
| 2017 | 473.12 Thousand EUR | 0.26% |
| 2016 | 471.87 Thousand EUR | -1.78% |
| 2015 | 480.43 Thousand EUR | 0.72% |
| 2014 | 477.01 Thousand EUR | -9.72% |
| 2013 | 528.36 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q4 | 417 Thousand EUR | 0.0% |
| 2023 FY | 417 Thousand EUR | 11.8% |
| 2023 Q2 | 401 Thousand EUR | 0.0% |
| 2022 FY | 373 Thousand EUR | -4.85% |
| 2022 Q2 | 355 Thousand EUR | 0.0% |
| 2022 Q4 | 373 Thousand EUR | 0.0% |
| 2021 FY | 392 Thousand EUR | 22.5% |
| 2021 Q1 | 375 Thousand EUR | 17.19% |
| 2021 Q2 | 434 Thousand EUR | 15.73% |
| 2021 Q4 | 392 Thousand EUR | 0.0% |
| 2020 FY | 320 Thousand EUR | -17.31% |
| 2020 Q2 | 349 Thousand EUR | 0.0% |
| 2020 Q4 | 320 Thousand EUR | 0.0% |
| 2019 Q4 | 387 Thousand EUR | 0.0% |
| 2019 FY | 387 Thousand EUR | -5.61% |
| 2019 Q2 | 433 Thousand EUR | 0.0% |
| 2018 Q4 | 410 Thousand EUR | 0.0% |
| 2018 FY | 410 Thousand EUR | -13.34% |
| 2018 Q2 | 516.4 Thousand EUR | 0.0% |
| 2017 FY | 473.12 Thousand EUR | 0.26% |
| 2017 Q4 | 473.12 Thousand EUR | 0.0% |
| 2017 Q2 | 500.77 Thousand EUR | 0.0% |
| 2016 Q4 | 471.87 Thousand EUR | 0.0% |
| 2016 FY | 471.87 Thousand EUR | -1.78% |
| 2016 Q2 | 483.43 Thousand EUR | 0.0% |
| 2015 FY | 480.43 Thousand EUR | 0.72% |
| 2015 Q4 | 480.43 Thousand EUR | 0.0% |
| 2014 FY | 477.01 Thousand EUR | -9.72% |
| 2013 FY | 528.36 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -88.688% |
| ABIVAX Société Anonyme | 1.00 EUR | -41699900.0% |
| Adocia SA | 272 Thousand EUR | -53.309% |
| Aelis Farma SA | 53 Thousand EUR | -686.792% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 76.048% |
| genOway Société anonyme | 982.75 Thousand EUR | 57.568% |
| IntegraGen SA | 311.44 Thousand EUR | -33.89% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -153.308% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 137.613% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 65.947% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 449.903% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -358.242% |
| Valbiotis SA | 1 Million EUR | 58.507% |
| TheraVet SA | 123.34 Thousand EUR | -238.084% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -41699900.0% |
| argenx SE | 281.12 Million EUR | 99.852% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 66.905% |
| DBV Technologies S.A. | 1.00 USD | -41699900.0% |
| Galapagos NV | 73.97 Million EUR | 99.436% |
| Genfit S.A. | 4000.00 EUR | -10325.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -41699900.0% |
| Innate Pharma S.A. | 1.00 EUR | -41699900.0% |
| MaaT Pharma SA | 190 Thousand EUR | -119.474% |
| MedinCell S.A. | -6.71 Million EUR | 106.211% |
| Nanobiotix S.A. | 200 Thousand EUR | -108.5% |
| Onward Medical N.V. | 936 Thousand EUR | 55.449% |
| Oryzon Genomics S.A. | 6029.00 EUR | -6816.57% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -225.781% |
| Pharming Group N.V. | 51.38 Million EUR | 99.188% |
| Poxel S.A. | 2.95 Million EUR | 85.893% |
| GenSight Biologics S.A. | 1.00 EUR | -41699900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.96% |
| Valneva SE | 44.46 Million EUR | 99.062% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -41699900.0% |